海隆控股(01623.HK)擬發行2億美元優先票據
格隆匯9月20日丨海隆控股(01623.HK)公佈,公司已把最高接納金額定於2億美元,並決定接納全部有效呈交的2020年票據。公司接納購買每1,000美元本金額的202年票據購買價為1,003.75美元。
因此,根據要約條款,公司將支付:(i)就接納購買所有該等2020年票據的總購買價145,429,332.50美元;及(ii)產生的合計應計利息,款額為2,742,772.46美元。
此外,公司將發行2億美元於2022年到期8.25釐優先票據。票據要約價將為票據本金額的99.480%。公司擬把同步新資金髮行的所得款項淨額主要用於為現有離岸債務再融資,以及作為營運資金及供一般企業用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.